Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R O Day

Showing results (61-70 of 188) with videos related to

Pageof 19
Sort By:
The Medical Journal of Australia|August 7, 1995
Non-steroidal anti-inflammatory drugsA G Johnson, D I Quinn, R O Day
British Journal of Clinical Pharmacology|October 1, 1994
Clinical response to non-steroidal anti-inflammatory drugs in urate-crystal induced inflammation: a simultaneous study of intersubject and intrasubject variabilityJ S Walker, T V Nguyen, R O Day
The Medical Journal of Australia|April 28, 1986
Drugs involved in self-poisoning: verification by toxicological analysisJ E Ray, D K Reilly, R O Day
Internal Medicine Journal|June 5, 2007
Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?C Y Lu, K M Williams, R O Day
Internal Medicine Journal|February 22, 2013
A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosusS J Carmichael, R O Day, S E Tett
The Medical Journal of Australia|July 2, 1990
A functional psychosis precipitated by quinidineA G Johnson, R O Day, W A Seldon
Internal Medicine Journal|November 6, 2014
Does the availability of therapeutic drug monitoring, computerised dose recommendation and prescribing decision support services promote compliance with national gentamicin prescribing guidelines?N Diasinos, M Baysari, S Kumar, et al.
Internal Medicine Journal|January 18, 2006
Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?C Y Lu, K M Williams, R O Day
Clinical Pharmacokinetics|May 1, 1983
Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylatesR O Day, D D Shen, D L Azarnoff
British Journal of Clinical Pharmacology|August 1, 1991
1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effectD J Birkett, J O Miners, R O Day
Pageof 19

Showing results (61-70 of 188) with videos related to

Sort By:
Pageof 19
The Medical Journal of Australia|August 7, 1995
Non-steroidal anti-inflammatory drugsA G Johnson, D I Quinn, R O Day
British Journal of Clinical Pharmacology|October 1, 1994
Clinical response to non-steroidal anti-inflammatory drugs in urate-crystal induced inflammation: a simultaneous study of intersubject and intrasubject variabilityJ S Walker, T V Nguyen, R O Day
The Medical Journal of Australia|April 28, 1986
Drugs involved in self-poisoning: verification by toxicological analysisJ E Ray, D K Reilly, R O Day
Internal Medicine Journal|June 5, 2007
Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?C Y Lu, K M Williams, R O Day
Internal Medicine Journal|February 22, 2013
A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosusS J Carmichael, R O Day, S E Tett
The Medical Journal of Australia|July 2, 1990
A functional psychosis precipitated by quinidineA G Johnson, R O Day, W A Seldon
Internal Medicine Journal|November 6, 2014
Does the availability of therapeutic drug monitoring, computerised dose recommendation and prescribing decision support services promote compliance with national gentamicin prescribing guidelines?N Diasinos, M Baysari, S Kumar, et al.
Internal Medicine Journal|January 18, 2006
Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?C Y Lu, K M Williams, R O Day
Clinical Pharmacokinetics|May 1, 1983
Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylatesR O Day, D D Shen, D L Azarnoff
British Journal of Clinical Pharmacology|August 1, 1991
1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effectD J Birkett, J O Miners, R O Day
Pageof 19